Pfizer and Biontech planning to file for emergency use of Covid19 Vaccine – Covid-19: Pfizer wants to allow emergency use of vaccine from December

0
7


World Desk, Amar Ujala, New York
Updated Fri, 20 Nov 2020 7:05 PM IST

Read Amar Ujala e-paper
anywhere anytime.

*Yearly subscription for just ₹299 Limited Period Offer. HURRY UP!

Hear the news

Kovid-19 vaccine maker Pfizer Inc. and BioNotech said on Friday that they were going to apply for permission for the emergency use of the vaccine. The companies said that they are doing this to get permission to use the Kovid-19 vaccine in the US from December next month.

American pharmaceutical company Pfizer and German company Bioentech have joined hands to provide relief to the entire world affected by the global pandemic Kovid-19. Earlier this week, the company claimed that its potential vaccine proved to be up to 95% effective in the final analysis of the trial.

The company said in a statement that the Food and Drug Administration (FDA) may allow vaccine supplements to be given to high-risk populations in the US by the end of December. In their application, the two companies have also attached safety data on about 100 children between the ages of 12 and 15 years.

Pfizer and Bio-Entech made a big announcement about the vaccine on Wednesday. He said that his mRNA-based potential vaccine ‘BNT162B2’ was found to be up to 95 per cent effective in the final analysis of the Phase III trial and that it was effective for people over 65 years of age.

Vaccination for Covid-19 in Italy will start in January
Those in Italy who wish to take vaccine supplements to protect against Kovid-19 will probably receive all vaccine doses by September next year. Italy’s Special Commissioner for Virus Emergencies Damonico Arcari gave this information on Thursday. He said that the first dose would be available by January.

Arkari said that Italy is to receive 3.4 million doses of the Pfizer vaccine after the second week of January, which is sufficient to deliver the required two doses to 1.6 million out of Italy’s six million people, under the European Union procurement program. Preference will be given to the elderly and those at higher risk.

Kovid-19 vaccine maker Pfizer Inc. and BioNotech said on Friday that they were going to apply for permission for the emergency use of the vaccine. The companies said that they are doing this to get permission to use the Kovid-19 vaccine in the US from December next month.

American pharmaceutical company Pfizer and German company Bioentech have joined hands to provide relief to the entire world affected by the global pandemic Kovid-19. Earlier this week, the company claimed that its potential vaccine proved to be up to 95% effective in the final analysis of the trial.

The company said in a statement that the Food and Drug Administration (FDA) may allow vaccine supplements to high-risk populations in the US by the end of December. In their application, the two companies have also attached safety data on about 100 children between the ages of 12 and 15 years.

Pfizer and Bio-Entech made a big announcement about the vaccine on Wednesday. He said that his mRNA-based potential vaccine ‘BNT162B2’ was found to be up to 95 per cent effective in the final analysis of the Phase III trial and that it was effective for people over 65 years of age.

Vaccination for Covid-19 in Italy will start in January
Those in Italy who wish to take vaccine supplements to protect against Kovid-19 will probably receive all vaccine doses by September next year. Italy’s Special Commissioner for Virus Emergencies Damonico Arcari gave this information on Thursday. He said that the first dose would be available by January.

Arkari said that Italy is to receive 3.4 million doses of the Pfizer vaccine after the second week of January, which is sufficient to deliver the required two doses to 1.6 million out of Italy’s six million people, under the European Union procurement program. Preference will be given to the elderly and those at higher risk.

LEAVE A REPLY

Please enter your comment!
Please enter your name here